Table 2 Clinical outcomes
Characteristic | Total (n = 100) | Isavuconazole (n = 33) | Voriconazole (n = 34) | Posaconazole (n = 33) | P-value |
|---|---|---|---|---|---|
Composite safety, n (%) | 40 (40) | 8 (24.2) | 19 (55.9) | 13 (39.4) | 0.028 |
QTc prolongation following drug initiation, n (%) | 28 (28) | 4 (12.1) | 13 (38.2) | 11 (33.3) | 0.037 |
LFT elevation, n (%) | 8 (8.0) | 2 (6.1) | 3 (8.8) | 3 (9.1) | 0.876 |
Adverse reaction, n (%) | 9 (9) | 2 (6.1) | 5 (15.2) | 2 (6.1) | 0.356 |
Change in QTc, milliseconds | 7.5 ± 42.0 | − 18.0 ± 37.6 | 20.5 ± 37.8 | 22.6 ± 38.6 | 0.001 |
Max QTc, milliseconds | 464.2 ± 35.1 | 460.0 ± 29.5 | 465.4 ± 33.8 | 467.4 42.2 | 0.739 |
Change in ALT, units/L | 93.2 ± 393.6 | 95.1 ± 440.3 | 105.6 ± 448.5 | 78.5 ± 281.2 | 0.964 |
Change in AST, units/L | 192.4 ± 894.7 | 159.5 ± 717.3 | 259.2 ± 1226.2 | 155.4 ± 629.8 | 0.875 |
Duration of inpatient therapy, days | 12.9 ± 15.3 | 11.9 ± 11.9 | 12.6 ± 10.8 | 14.3 ± 21.5 | 0.809 |
Mortality, n (%) | 48 (48) | 15 (45.5) | 16 (47.1) | 17 (51.5) | 0.878 |
ICU length of stay, days | 12.7 ± 37.1 | 10.0 ± 15.0 | 11.1 ± 23.2 | 17 ± 58.7 | 0.718 |
Hospital length of stay, days | 32.9 ± 37.4 | 31.8 ± 25.9 | 28.2 ± 19.5 | 38.7 ± 56.7 | 0.515 |
30 day readmission, n (%) | 29 (42) | 8 (34.78) | 7 (30.4) | 14 (60.9) | 0.077 |
Recurrent infection, n (%) | 9 (14.1%) | 1 (4.5%) | 4 (19.1%) | 4 (19.1%) | 0.230 |
Percent change in immunosuppression dose | − 46.1 [− 27.8, − 57.8] | − 34.3 [− 4.04, − 46.5] | − 48.4 [− 35.1, − 65.9] | − 46.4 [− 35.1, − 65.9] | 0.029 |